modelC02CA01

Diagram of C02CA01

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Prazosin
ATC code:C02CA01
route:oral
compartments:2
dosage:5mg
volume of distribution:307L
clearance:13.5L/hr
other parameters in model implementation

Prazosin is an alpha-1 adrenergic receptor antagonist primarily used for the treatment of hypertension and symptoms of benign prostatic hyperplasia. It is also used off-label in the management of post-traumatic stress disorder (PTSD)-associated nightmares in adults. Prazosin is an approved and commonly used medication today.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult male subjects after oral administration.

References

  1. Kwon, YH, et al., & Chun, IK (2007). Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. Drug development and industrial pharmacy 33(8) 824–829. DOI:10.1080/03639040601012999 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17729099

  2. Liu, M, et al., & Liu, H (2012). Pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. Chirality 24(12) 1047–1050. DOI:10.1002/chir.22095 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22887707

  3. Yan, M, et al., & Zhu, YG (2010). Determination of metoclopramide in human plasma by LC-ESI-MS and its application to bioequivalance studies. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 878(11-12) 883–887. DOI:10.1016/j.jchromb.2010.02.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20189472

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)